A recent study demonstrated that treatment of lung cancer or squamous cell carcinoma cells with a combination of erlotinib and the novel CK2 inhibitor CX-4945 led to enhanced inhibition of PI3K/Akt signaling and increased anti-tumor efficacy in vitro and in vivo[44]. The gene discussed is PIK3CD; the disease is lung cancer.